BACK TO HOMEPAGE
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,400 people in nearly 40 countries, the company generated revenue of €5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Sanofi Genzyme and Regeneron
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.
Novartis Pharma AG
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world.
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit.
Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions.
LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10,133 million.
For more information please visit www.LEO-Pharma.com
Janssen Pharmaceutica NV
At Janssen, it is our mission to redefine immune disease treatments through transformational and accessible therapies and regimens.
The Immunology Therapeutic Area of Janssen Research & Development LLC has over 20 years’ work in therapies for autoimmune and inflammatory disease.
Today, our portfolio has expanded to include novel, oral small molecules, and new biologic platforms (both at investigational stage), and we continue our research into challenging areas of high unmet medical need.
Our work is based on deep scientific understanding of the diseases we treat, helping drive discovery. Our scientists in research and clinical development collaborate with medical affairs, market access and commercial teams to enable learnings, that run from bench to bedside, with the common goal of advancing science to improve patients’ lives.
We look to remain a leader in optimising and tailoring therapeutic advances, to target the right treatment for the right person in every part of the world.
Galderma is the world’s largest independent dermatology company, present in approximately 100 countries. Since our inception in 1981, we have been driven by a complete dedication to dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Focused on the needs of consumers and patients, we work in partnership with healthcare professionals to ensure superior outcomes. Because we understand that the skin we’re in shapes our life stories, we are advancing dermatology for every skin story.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
Almirall is a global, research-focused biopharmaceutical company based in Barcelona. We collaborate with scientists and healthcare professionals to address patients’ needs, provide them with innovative treatments, and make our Noble Purpose a reality: “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”.
We invest in groundbreaking medical dermatology products to bring our innovative solutions to patients in need, with the help of our scientists based in our three R&D sites in Spain, Germany and the US. The backbone of Almirall’s activities is to guarantee the health and well-being of our patients, providing our experience and knowledge to design therapies adapted to their needs.
We have carefully selected the skin conditions in which we are confident we can have the biggest impact by adding valuable solutions to improve the life of those patients living with them: psoriasis, actinic keratosis, atopic dermatitis, and acne.
L’Oréal Dermatological Beauty
L’Oréal Dermatological beauty is the world leader in the medical beauty skincare market, with a mission to empower each and everyone with the most advanced integrative skin management that can preserve, protect, treat or enhance skin for long-lasting healthy beauty.
Its portfolio of highly complementary brands – La Roche-Posay, Vichy, SkinCeuticals, CeraVe- meets the growing expectations and concerns of patients: scientifically proven innovation and efficacy, product tolerance and safety, naturalness and positive impact on the quality of life and the environment.
With a presence in all health care distribution channels – pharmacies, drugstores, doctors’ offices, own stores and e-commerce-, L’Oréal Dermatological beauty fully integrates healthcare professionals and particularly dermatologists in the development of
– Hair and skin care products to answer a wide range of skin concerns from esthetics to pathological issues.
– Digital devices to evaluate the skin and accompany treatments.
This year, for this 2nd Virtual EADV, L’Oréal Dermatological Beauty will be present as a Major Sponsor offering a complete virtual skin experience thanks to its medical brands.
Anchored in a resolutely humanist Reason for Being, our two complementary activities – medicine (Dermatology, Oncology Innovation, etc.) and dermo-cosmetics (Eau Thermale AVENE, DUCRAY, A-DERMA) allow us to have an approach overall health (prevent, treat, support) which is in line with the new expectations of dermatologists, patients and consumers.
We take care of life by imagining and developing innovative solutions inspired by consumers and patients and by contributing to the well-being of everyone from health to beauty.
The Group defines its “Raison d’être” and reflects the specificity of Pierre Fabre since its creation: 60 years of pharmaceutical expertise, inventor of dermo-cosmetics.
Our “raison d’être”: “Every time we take care of one person, we make the world a better place”
Amgen (Europe) GmbH
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent
biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen
Bristol Myers Squibb
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.
Boehringer Ingelheim International GmbH
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the global pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals.
Our goal is to discover and develop first-of-their-kind therapies. With a deep understanding of molecular pathways, we are pioneering scientific breakthroughs that target, repair and prevent many inflammatory diseases. By building on long-term external collaborations we strive to bring treatment breakthroughs to patients in the shortest time. Our immunology product pipeline is well stocked with a number of promising substances.
These include auto-inflammatory skin diseases and chronic inflammatory bowel diseases.
We won’t rest until we can give people the chance to live the life they want.
More information can be found on www.boehringer-ingelheim.com.
Eucerin by Beiersdorf
At Beiersdorf we have been caring about skin since 1882. Throughout our history we have built trust by staying close to our consumers and developing innovative skin care brands that are tailored to their needs. We work as one global team, with one focus: making people feel good in their skin. Everywhere. Every day. As we head into the future, we want to become the number one skin care company in the world.
medac is a privately held pharmaceutical company with a growing pharmaceutical and diagnostics business. Medicinal products from medac support doctors and patients throughout the world in overcoming acute and chronic diseases in the indication areas of oncology, haematology, urology and autoimmune disorders. In addition, medac develops and markets special diagnostic test systems.
Since 1970 medac has been committed to unifying therapeutic and diagnostic areas under one roof.
Since 1977, BIODERMA, NAOS’s dermatological laboratory, has been placing its skin biology expertise at the service of dermatology.
We believe that the skin has all the necessary resources to protect, regulate and regenerate itself, but its ecosystem can be disrupted, requiring specific support. This unique approach that respects the skin is one of the principles of ecobiology that was inspired by NAOS 40 years ago.
Designed in Aix-en-Provence and manufactured in France, our products act:
– as prevention, each day, to maintain skin’s physiological balance and protect it against aggressions
– before, during and after dermatological treatments to improve patients’ skin health
– right from cleansing, because removing impurities while preserving the hydrolipidic film is the first step to take care of the skin
Today, we partner with +150,000 healthcare professionals to create products that are validated by clinical studies and that combine efficacy and tolerance for each skin sensitivity.
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies. With its corporate philosophy of “caring for life”, the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
Canfield Scientific Inc.
Canfield Scientific is the global leader in developing and distributing imaging systems for the medical and skin care industries. Used in hospitals, medical and aesthetic practices, medical spas, and skin care and wellness centers, Canfield’s advanced photographic imaging solutions are an integral part of consultations, built around a common patient image chart. From AI-driven iPad applications, to full-body 3D photography, thousands of surgical and non-surgical consultations begin with images captured by Canfield’s powerful imaging tools that improve communications, align doctor-patient expectations, facilitate treatment planning, and highlight results.
VivaScope GmbH is a Munich-based company that operated as a subsidiary MAVIG GmbH for over 15 years and has been operating as an independent company since January 2021. They are a market specialist for developing and distributing of confocal laser scanning microscopes in various fields of medicine and the cosmetics industry.
Confocal laser scanning microscopy enables rapid differentiation between pathogenic and healthy tissue.
In the IN VIVO field, the VivaScope devices enable a non-invasive examination that is entirely painless for patients, an “optical biopsy” of the skin. Based on the visualised cellular structures, a statement about benignancy/malignancy is possible immediately.
In the EX VIVO field, the VivaScope device enable a “digital frozen sectioning”. An H&E-like image is generated from freshly excised tissue within a few minutes. With this technology, a histological examination of a pathologist is possible in real time, regardless of location.
Incyte Biosciences International Sàrl
Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
Since 2002 Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build sustainable value for our stakeholders.
Incyte’s unique expertise in medicinal chemistry and biology have enabled us to create a diversified pipeline of clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing portfolio of medicines across Oncology and Inflammation & Autoimmunity.
Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.
For more information, visit Incyte.com and follow @Incyte.
Hand-built by our skilled technicians at our facilities in Southern California, DermLite® devices created modern polarized pocket dermoscopy, today’s gold standard in skin cancer screening. Our patented polarization technology allows for the clearest vision deep into the lesion, and our signature color spectrum has been curated to highlight lesion structures critical for early detection of skin cancers.
mesoestetic Pharma Group
mesoestetic Pharma Group is an internationally recognized pharmaceutical laboratory in the field of dermo cosmetics and aesthetic medicine. With its headquarters in Viladecans (Barcelona). It develops, produces and markets extremely effective treatments endorsed by scientific studies. Its manufacturing and control processes adhere to the exacting standards of the pharmaceutical industry.
It is because to the effectiveness of its products and its 35+ years of experience, physicians, cosmetic professionals, and end users all over the world place their trust in mesoestetic.
HEINE – Quality made in Germany
As a global leader in the manufacture of primary diagnostic instruments with over 500 employees, HEINE Optotechnik has been a 100 % family owned and managed company for more than 70 years. We continue to develop and manufacture HEINE instruments at our facilities in Germany, where we combine decades-long experience and craftsmanship with the most modern manufacturing technologies.
We are represented in over 120 countries around the world, with subsidiaries in Australia, the US and Switzerland as well as 3,000 representatives, importers and specialist dealers.
We look forward to hearing from you – and would like to know more about your opinions, desires and suggestions regarding our products.
The Pharmaceris brand offers safe specialist dermocosmetics that are specifically targeted to meet skincare needs and assist in the treatment of most common skin problems.
Pharmaceris dermocosmetics have been developed by a team of experts who, by combining dermatological solutions and advanced cosmetic formulas, have managed to obtain preparations capable of addressing a number of different difficult-to-treat skin problems.
Systematically arranged into 14 product lines, these preparations contribute to developing comprehensive skin care programmes with proven effectiveness and safety. All formulas have been dermatologically tested, with some of them even clinically tested on patients suffering from skin problems, by independent research institutes and hospitals.
Amryt Pharma DAC
Amryt Pharma is a global biopharmaceutical company dedicated to developing and delivering innovative novel treatments to help improve the lives of patients with rare and debilitating diseases and of those who care for them. A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity and ethical practice. We aim to forge partnerships and collaborations that work for all. By listening to patients, caregivers, physicians, and the wider communities, we aim to create a clear path for our transformative medicines to reach those that need them.
siHealth helps others to get the best health benefits through a controlled relationship with nature. siHealth exists to bridge the gap between medicine and wellness – both in the way doctors practice and the way patients look after their long-term health – providing the latest innovations in environmental health, photobiology, and advanced image and data analytics technologies. Every living organism interacts with an external environment in order to survive, grow, change and enjoy its life!
However, our relationship with nature varies; some days it can be our best friend, but it can also be a threat to our health and wellbeing.
Who has never fallen asleep on a sunny spring day, only to wake up with severe sunburn? Who has never experienced jet lag and poor sleep due to the sudden change of daylight hours?
siHealth’s claim is to provide digital solutions that not only make our environment easy to enjoy, but also to use the benefits offered to us by it to prevent diseases and even to treat already existing conditions.
BELLA AURORA LABS
BELLA AURORA LABS S.A. is a Spanish-owned company specialized in offering solutions to specific needs such as skin pigmentation disorders.
Bella Aurora brand, as part of Bella Aurora Labs, has a history that dates back 130 years. Its laboratories specialize in the behavior of the melanocyte and the cellular mechanisms involved in the production process of melanin, the pigment that causes skin coloration.
At the forefront of innovation, their own patents have revolutionized the hypopigmentation and skin hyperpigmentation market.
Bella Aurora already has a solid presence in Europe, Asia and the US and is on a mission to become an established world leader in skin pigmentation and the number one for eliminating dark spots and white patches.
Sofwave™ breakthrough, non-invasive Synchronous Ultrasound Parallel Beam Technology SUPERB™ FDA-cleared to improve facial lines and wrinkles.
Sofwave Synchronous Ultrasound Parallel Beam Technology SUPERB™, answers the growing demand for Non-Invasive treatments that deliver noticeable wrinkle reduction, with its 7 cooled transducers directly coupled to the epidermis, creating a unique 3D array of volumetric, cylindrical-shaped thermal zones that deliver continuous parallel energy simultaneously to coagulate more tissue areas more quickly at a depth of 1.5 mm – mid-dermis to improve skin effect in half the treatment time of other technologies, no matter the skin type
Link to about us: https://bit.ly/2zE2S1t
ARENA PHARMACEUTICALS is in a rapidly changing global market, where we work with a sense of urgency every day to understand the needs of all our stakeholders, identify bold, sometimes disruptive, ideas to discover and develop medicines for patients, and relentlessly execute until it’s done.
Our Dermatology research portfolio: etrasimod is an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator that in November 2020 delivered topline results in a phase 2b trial for atopic dermatitis (ADVISE) and is moving forward into a Phase 3 registrational program. Etrasimod is also being evaluated in a phase 2 program in alopecia areata.
Etrasimod is an investigational compound, and is not approved by any health authority.
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating its lead candidate, efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan. For more information, visit www.argenx.com and follow us on LinkedIn and Twitter.
Respiratory & Immunology is one of AstraZeneca’s three therapy areas and is a key growth driver for the Company.
AstraZeneca is an established leader in respiratory care with a 50-year heritage. The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death. The Company’s early respiratory research is focused on emerging science involving immune mechanisms, lung damage and abnormal cell-repair processes in disease and neuronal dysfunction.
With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas. The Company’s growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential, in areas including rheumatology (including systemic lupus erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases. AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.
WCD 2023 Singapore
Singapore was chosen as the host city for the 25th World Congress of Dermatology 2023. The congress theme is “Dermatology Beyond Borders”. The congress will provide the occasion for clinicians, researchers, industry and other partners to work towards extending the boundaries of dermatology. The 25th WCD will present a broad, deep and interesting scientific programme that will cover all clinical areas, enhance patient and community engagement. The Suntec Singapore Convention and Exhibition Centre, with state-of-the-art conference facilities and services, will be the venue for the congress. Few notes about Singapore: it is a democratic and secular country. Visitor attractions are plentiful and include great museums, modern business districts, historical precincts, tropical parks and walks and a vibrant cultural scene. The food culture is world-famous, drawing from multicultural roots mixed with international influences.
For updates on WCD 2023, check out our website and social channels.
KEEP IN TOUCH
Stay informed about latest EADV information.
Congresses, Education, JEADV, Membership, Newsletter...
YES, KEEP ME INFORMED
of Dermatology and Venereology
Via S. Balestra 22B
6900 Lugano Switzerland
+41 91 973 45 20
Copyright 2021 EADV
Only trust information from our official website: eadv.org